China PT-141 Factory, Products
Order Verified Product →
Explore our immediate-dispatch catalogue of lab-tested peptide APIs, metabolic reference agents, and high-yield raw chemical building blocks manufactured in certified facilities.
Cas 288573-56-8 represents an indispensable chemical intermediate utilized across advanced pharmacological research, specialized molecular engineering, and complex stereoselective synthesis. For high-throughput laboratories and formulation manufacturers, qualifying a primary supplier demands granular insight into structural characteristics, impurity profiling, and synthesis predictability.
| Analytical Parameter | Certified Pharmacopeia / Enterprise Standard | Instrumental Method | Batch Verification Status |
|---|---|---|---|
| Chemical / IUPAC Identifier | Target Intermediate / CAS Registry Reference | Chemical Structure Deposition | ✓ Qualified |
| CAS Number | 288573-56-8 | Registry Validation Check | ✓ Authentic |
| Physical Appearance | Off-white to pure white crystalline powder | Visual & Microscopic Inspection | ✓ Compliant |
| Purity (Area Normalization) | Standard Grade: ≥98.0% | Ultra-Refined: ≥99.5% | RP-HPLC (C18 Column, UV Detector) | ✓ Validated |
| Identification (ID) | Conforms to Reference Standard Spectrum | 1H-NMR Spectroscopy & LC-MS (ESI) | ✓ Verified |
| Residual Solvents | Ethanol < 5000 ppm, Methanol < 3000 ppm, DCM < 600 ppm | Headspace Gas Chromatography (GC-MS) | ✓ Below Limits |
| Heavy Metals (Pb, Cd, As, Hg) | Total Heavy Metals ≤ 10 ppm (Individually ≤ 1.5 ppm) | ICP-MS Standard Operating Procedure | ✓ Trace Level |
The functional efficacy and chemical demand for Cas 288573-56-8 diverge based on territorial research objectives, local industrial infrastructures, and regulatory frameworks across key geopolitical markets.
In the biotechnology belts of Boston, San Francisco, and the Research Triangle, Cas 288573-56-8 is predominantly procured as a high-purity molecular substrate for hit-to-lead chemical discovery and receptor kinetics research. Stringent institutional oversight by the FDA mandates sub-ppb metallic impurity thresholds and exhaustive documentation (COA, FTIR, LC-MS) prior to introduction in animal model assay pipelines.
European pharmaceutical contract development and manufacturing organizations (CDMOs) leverage Cas 288573-56-8 in multi-step stereospecific reaction pathways. Sourcing priority centers on compliance with EU REACH registration dossiers, solvent threshold parameters governed by EMA guidance, and lifecycle environmental audits verifying low-emission, green-solvent crystallization protocols.
Across emerging biomedical manufacturing clusters in Singapore, South Korea, and India, the compound is heavily utilized for commercial pilot batches and intermediate bulk conversion. Procurement focuses on batch-to-batch chromatographic reproducibility, continuous volume supply guarantees, and optimized total cost-of-ownership structures for large-scale production cycles.
Transitioning from legacy batch-flask condensation to continuous-flow microreactors represents the defining milestone in optimizing Cas 288573-56-8 production efficiency, reducing by-product generation, and maintaining crystalline stability.
Historically reliant on atmospheric thermal reactors with prolonged reaction residency times. This traditional approach yields between 78% and 84% crude intermediate, requiring repeated solvent crystallizations that elevate VOC output and create unwanted regioisomeric impurities demanding intensive downstream cleanup.
Current tier-1 manufacturing facilities employ continuous-flow synthesis modules. Precise residence time control and algorithmic temperature profiling suppress thermal decomposition. Chromatographic yields exceed 94% with net purity routinely passing ≥99.2% directly out of preparative chromatography loops.
Emerging research directions prioritize enzymatic stereoselective conversion and closed-circuit CO2 supercritical drying. This cutting-edge pathway eliminates halogenated hydrocarbons, minimizes critical carbon footprints, and ensures zero toxic heavy-metal contamination for strict clinical-grade projects.
China’s comprehensive chemical manufacturing infrastructure provides enterprise procurement officers with exceptional security against upstream disruption, raw material spikes, and lead-time volatility.
Direct geographic integration with domestic petrochemical refineries and starting material synthesis hubs insulates Cas 288573-56-8 production from international feedstock shortages, guaranteeing uninterrupted synthesis schedules even during global logistic constraints.
Advanced automation and high-capacity reaction vessels (up to 5,000L glass-lined units) generate dramatic unit-cost reductions. Buyers benefit from competitive tiered contract pricing without sacrificing analytical rigor, documented assay levels, or batch integrity.
State-of-the-art analytical facilities equipped with Agilent HPLC arrays, Bruker 400MHz NMR, and Shimadzu GC-MS platforms operate 24/7 on-site, expediting internal release workflows from weeks to hours without outsourcing to remote diagnostic hubs.
Factory-floor customization supports diverse containment solutions—ranging from 1mg–100g amber cryogenic vials to 25kg foil-lined fiber drums. Direct freight corridors through Shanghai and Shenzhen guarantee rapid door-to-door delivery worldwide.
Navigating the international procurement space requires deep situational awareness regarding speculative market pricing, counterfeit material proliferation, and the regulatory classification of high-demand fine chemicals.
Global commercial pricing for Cas 288573-56-8 shows stark disparities. Research labs often encounter low-cost broker quotes that mask sub-95% crude grades contaminated with heavy-metal residues or optical enantiomer impurities. Authentic enterprise suppliers maintain transparent cost-per-gram structures linked directly to verifiable HPLC assay certifications.
The rise of unauthorized digital chemical brokers has amplified incidents of mislabeled intermediates and fabricated COAs. Establishing direct partnerships with primary production facilities—such as Miaoou Technology—guarantees genuine materials backed by live testing data and third-party lab verification capabilities.
Forward-thinking pharmaceutical procurement directors increasingly secure 12- to 36-month rolling supply agreements. Long-term supplier framework contracts mitigate spot-market price spikes, lock in reserve production slots, and ensure constant raw chemical availability across multi-year trials.
Cross-border chemical procurement requires rigorous compliance safeguards. Every shipment of Cas 288573-56-8 is accompanied by complete regulatory documentation aligned with international customs and hazardous substance protocols.
Clear, authoritative technical answers addressing common questions raised by chemical engineers, research lab buyers, and corporate compliance managers.
Every commercial or research batch undergoes immediate analytical screening via HPLC and mass spectrometry within 24 hours of synthesis completion. The resulting Certificate of Analysis (COA) is issued instantly alongside full raw chromatographic profiles upon order confirmation.
For stereoselective intermediates, our production plants incorporate chiral stationary phase HPLC (CSP-HPLC) and polarimetry to identify and limit enantiomeric excess (ee) variations. We guarantee chiral purity exceeding ≥99.0% for critical asymmetrical synthesis applications.
Yes. Depending on user specifications and compound sensitivity, materials are packaged under continuous argon/nitrogen positive pressure in fluorinated HDPE bottles, multi-layer aluminum vacuum foil envelopes, or specialized glass ampoules designed to eliminate ambient humidity ingress.
Standard material is stored at −20°C in dedicated temperature-monitored, desiccated clean rooms. When maintained in unopened factory packaging under prescribed parameters, the documented retest period is 24 months from the initial QC release date without significant degradation.
Broaden your formulation and synthetic discovery capabilities with our inventory of analytical-grade reference molecules, hormonal agonists, and premium synthetic precursors.
